/** blogpostTitle: Sun Pharma in FY26 and Q1 FY27: Mix shift, India strength, and an Organon sized pivot blogpostSlug: sunpharma-fy27 blogpostCoverImageDescription: Ultra realistic corporate finance scene showing a clean dashboard on a large monitor with a stacked revenue mix chart splitting five regions (India, US, Emerging Markets, Rest of World, API and Others) and a separate line chart trending gross margin rising from low 70s to about 80 over five years, plus a smaller card showing Q1 FY27 revenue and margin figures; neutral office lighting, modern boardroom table, no logos or readable text. blogpostShortTitle: Sun Pharma FY27: Mix shift and growth */

Sun Pharma in FY26 and Q1 FY27: Mix shift, India strength, and an Organon sized pivot

Sun Pharmaceutical Industries closed FY26 with gross sales of Rs 582 billion and entered FY27 with a steady first quarter. In Q1 FY27, gross sales rose 10.1 percent year on year to Rs 151,836 million. Gross margin expanded sharply to 80.5 percent, while EBITDA rose 2.7 percent to Rs 44,177 million. Reported net profit was Rs 28,948 million and adjusted net profit was Rs 30,894 million.

The quarter captured two forces playing out at the same time. One is the ongoing shift in product mix toward higher margin branded and innovative medicines. The other is the natural volatility in the US generics base, where lenalidomide has begun to fade and certain products are facing fresh competition. Management also reiterated that the proposed acquisition of Organon is progressing toward a close by early 2027, following shareholder approval.

A diversified base, with India leading near term

Sun Pharma’s FY26 revenue base was spread across multiple geographies. India remained the largest contributor, but international markets together still made up about two thirds of sales. The FY26 mix was 33 percent India formulations, 29 percent US formulations, 19 percent emerging markets, 15 percent rest of world, and 4 percent API and others.

In Q1 FY27, India formulations stood out. India sales were Rs 54,749 million, up 16 percent year on year, and accounted for 36.1 percent of consolidated quarterly sales. Management attributed the performance to broad based execution across therapy areas, focus on generating new prescriptions, brand building, and the benefit of prior field force expansion into tier 2 and tier 3 markets. The company also said it launched five new products in India during the quarter.

The US business moved in the opposite direction. US sales were USD 427 million in the quarter, down 9.7 percent year on year. Management linked the decline mainly to lenalidomide erosion, along with additional competition in certain generic products. There was also a quarter on quarter effect from seasonality in Levulan. US revenues were 26.6 percent of consolidated sales for the quarter.

Emerging markets formulations revenues were USD 311 million, up 4.2 percent year on year, slower than recent quarters. Management described the environment as impacted by geopolitical issues and difficult macroeconomic conditions in certain countries. Rest of world revenues were USD 218 million and were marginally lower versus the prior year quarter.

Financial snapshot (from company disclosures)

Innovative medicines is becoming the profit engine

The most structural theme in the deck is the rise of Innovative Medicines. The company stated Innovative Medicines contributed 22 percent of sales in FY26, up from 7.3 percent in FY18. In Q1 FY27, management said innovative sales rose 12.8 percent to USD 351 million and comprised 21.9 percent of sales for the quarter. Performance was described as driven by growth across the US and ex US markets and across products, notably Ilumya, Odomzo and Cequa.

Two newer US launches are also being positioned as the next growth drivers. Management shared early adoption indicators rather than revenue numbers. For Leqselvi, the company said prescriptions and prescriber count are rising each month, and in June it crossed 1,000 prescribers, alongside the strongest month since launch. For Unloxcyt, management said feedback from oncologists and dermatologists has been positive and more cancer centers and integrated health systems are adding it to formularies.

This mix shift is already visible in profitability metrics. Over FY22 to FY26, gross margin rose from 73.1 percent to 80.2 percent. EBITDA margin rose from 26.9 percent in FY22 to 30.3 percent in FY26. In Q1 FY27, gross margin touched 80.5 percent, and the CFO explicitly attributed this to better product mix.

That said, the quarter also showed that higher gross margin does not automatically translate into higher EBITDA margin every quarter. EBITDA margin was 28.9 percent in Q1 FY27, lower than Q1 FY26, and management pointed to lenalidomide benefits in the base quarter. Employee costs also rose, which management attributed to annual increments, additional field force required for the two US launches, some expansion in other markets for innovative medicines promotion, and foreign exchange translation.

Semaglutide expansion is a near term operating story

Beyond specialty, semaglutide is emerging as a tangible volume and execution topic, particularly in India and selected emerging markets. Management said Sun became the number 2 generic semaglutide injectable player in India, and claimed it is the only company in India offering a semaglutide auto injector. The device received positive feedback from health care professionals for smoother initiation and reducing needle phobia.

The emerging markets angle is starting to open up. Management said it has received approvals to manufacture and market the generic version of semaglutide injection in both Brazil and South Africa. The product has already been launched in South Africa, and a launch in Brazil is expected shortly through a partner. On supply chain preparedness, management said the API is manufactured in house, formulation is done in house, and the company is tied up with suppliers for device components.

While this does not come with explicit revenue guidance, it does signal a degree of operational readiness. It also shows how Sun’s vertical integration in APIs is intended to support launches in complex products that require both drug substance and device components.

The Organon transaction is the big strategic swing

Sun Pharma’s announcements and the earnings call both referenced the proposed acquisition of Organon. The company noted that Organon shareholders have approved the transaction and reiterated that closing is subject to remaining customary closing conditions, including regulatory approvals.

Management stated the acquisition is on track to close by early 2027, and later indicated completion is expected in Q4 of FY27, with an integration management office working on day one preparedness. At the same time, the CFO flagged that acquisition related charges have started. Q1 FY27 included a charge of Rs 1,617 million toward Organon acquisition related costs, with more charges expected in subsequent quarters and a substantial part of them back ended toward closing.

The company also guided that the effective tax rate has moved up, with Q1 FY27 ETR at 27.8 percent, and it expects a similar range going forward until the Organon closing.

Importantly, management emphasized balance sheet strength. The CFO stated Sun has net cash of 3.4 billion dollars at the consolidated level. A strong net cash position is relevant because integration spend, one time costs, and working capital requirements can rise during large cross border acquisitions.

Closing view

Sun Pharma’s FY26 and Q1 FY27 narrative is not just about growth. It is about composition. The company is leaning more on innovative medicines and branded businesses to keep gross margins high, while using India scale and field execution to sustain volume driven growth.

The next year is likely to test whether this mix shift can offset the ongoing softness in US generics and whether the Organon transaction can be executed without disrupting core operations. For now, management has reiterated high single digit consolidated revenue growth guidance for the year, and the quarter’s performance suggests a business that is still expanding, but with different engines firing at different speeds.